Finance

Novo Nordisk faces significant board changes and stock declines as it navigates governance conflicts with its foundation, aiming for future growth.

Biopharmaceutical funding surges as companies like Veradermics, Peptilogics, and BridGene advance innovative therapies through significant financing rounds.

Biotech funding surges as companies like Pelage, Kardigan, and Kailera secure millions to innovate treatments for hair loss, obesity, and cardiovascular diseases.

Investor reaction is showing how the industry is reacting to the President’s claims.

The company announced the plans as President visited the UK.

Drugmaker aims to simplify operations, speed up decision-making, and reinvest savings into diabetes and obesity growth opportunities in latest round of pharma layoffs.

The new funding is expected to fuel clinical progress for Alchemab’s muscle atrophy candidate and expand its AI-driven pipeline targeting immune and neurological diseases.

As the GLP market begins to settle, pharma companies and investors are looking to predict what comes next.

The collaboration provides BioArctic with an upfront payment of $30 million and potential milestone and royalty payments as the companies explore a novel drug candidate for severe neurological disorders.

The acquisition adds Furoscix, an FDA-approved furosemide infusion therapy for chronic heart failure and kidney disease, while strengthening MannKind’s pipeline and commercial presence in cardiometabolic and orphan lung diseases.

Under terms of the deal, Gilgamesh could receive up to $1.2 billion as bretisilocin progresses through clinical development for the treatment of major depressive disorder.

The acquisition aims to expand Kite Pharma’s capabilities in in vivo CAR T-cell therapy research and development.

The agreement values Mural Oncology at up to $36.2 million, with shareholders set to receive a base cash payment and potential additional consideration tied to closing net cash.

The collaboration will leverage Boehringer Ingelheim’s manufacturing expertise to accelerate AnGes’ HGF gene therapy toward regulatory approval and patient access.

The global biotherapeutics company announced that it will seek to streamline operations as part of a broader transformation to boost efficiency, refocus on core businesses, and reinvest in high-priority programs.

The collaboration will explore RNA-based small molecule drug candidates aimed at neurological conditions where existing treatment options remain limited.

Despite steady innovation and solid new drug approvals, the first half of 2025 was marked by a break from historical norms in financing, stock performance, and M&A for the pharma and biotech sectors.

The milestone payment is partially funded through Sarepta’s Arrowhead stock sale as both companies push forward with promising RNA interference programs.

Fate Therapeutics, Generation Bio, and ORIC Pharmaceuticals join a growing list of companies implementing workforce reductions as they restructure operations, extend cash runways, and focus resources on advancing lead clinical programs amid challenging market conditions.

The collaboration will fund early-stage clinical development of SB-4826, CIT’s first-in-class SUMO E1 inhibitor, for patients with relapsed or refractory follicular lymphoma.

The project aims to enhance AbbVie’s chemical synthesis capacity to support next-generation neuroscience, immunology, and oncology medicines, with construction beginning in 2025 and operations slated for 2027.

A new two-phase initiative aims to streamline facility approvals, reduce reliance on foreign pharmaceutical production, and bolster domestic supply chain resilience amid rising tariffs and reshoring investments.

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional payments and global royalty benefits if BioNTech’s acquisition of CureVac closes.

Eli Lilly’s investigational, once-daily oral GLP-1 receptor agonist orforglipron produced a 12% body weight reduction in a Phase III trial, slightly lower than Novo Nordisk’s Wegovy.

The company is streamlining its global workforce as part of a multi-year cost-cutting strategy, while raising its 2025 outlook on the strength of key pharmaceutical products.